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The PMI, which presupposes increased connectivity and broad interest of the American people in being active research participants or "partners, " intends to recruit a cohort representative of the US population at an unprecedented scalea novel approach for which not every detail can be controlled and not every potential pitfall can be anticipated. 2 The PMI is a "comprehensive effort" to explore health outcomes beyond those measurable in a clinic. 3 It will involve public and private partnerships working together to advance genomic medicine 4 and will depend heavily on understanding and supporting engaged patients. 5 Patient perspectives gleaned from these surveys (summarized in Tables 1 and 2 ) and GHS and HFHS experiences with other deliberative engagement (summarized in Table 3 ) provide insights for the PMI. Significant investment and attention must be directed to engagement in order to overcome the tendency for large collaborative projects to impose a one-size-fits-all approach to the planned communications with, recruitment of, and interactions with the prospective members of the PMI cohort.
Setting realistic expectations for the PMI and its prospective participants is critical, particularly regarding what information will be shared with participants, when and how it will be shared, and how to interpret and influence varying rates of participation once they are enrolled. Response rates for various activities will be highly dependent on the framing of the PMI during recruitment (e.g., whether passive participation would be permitted; whether recruitment and retention quotas set for healthcare provider organizations (HPOs) lead to the imposition of minimum participation thresholds that participants must meet to remain in the PMI cohort; or whether patients have the ability to moderate their own levels of minimal, moderate, or maximum involvement) and resources devoted to maximizing involvement (e.g., use of reminders, prompts, and targeted incentives).
Patients have indicated that learning something about their health is a main motivator for participating in the PMI, but the logistics and the scope of content have yet to be determined. Managing the PMI cohort and keeping participants interested if the processing pipeline is slow, complex, or not communicated will be difficult. Even the decision regarding who (a coordinating center or a local HPO) will serve as the point of contact for each participant is significant. The courage and energy required Key finding 7: reasons to participate 86.2%: "I think it is important to help researchers improve our understanding of genetics and disease risk, treatment, and prevention" 81.0%: "I think it is important to contribute to future research" 56.3%: "I think I could benefit from this type of research" 48.1%: "I think my family members could benefit from this type of research" 31.6%: "I feel a moral duty to society to participate in research" 22.7%: "I think it is fun to participate in research" to initiate communication are more burdensome to participants if the contact is unfamiliar. A centralized rather than local primary contact raises the possibility that sources of confusion or bad experiences with PMI will go unnoticed, unmeasured, and unaddressed as well as the possibility that individuals with questions or concerns will find it easier to stay silent or back out entirely rather than obtain clarification. Centralized messaging from the coordinating center to the emerging cohort in the earliest phase might not be as effective as orchestration by the coordinating center of a set of carefully tailored, flexible approaches to inspire eager, active participation in which the specific HPOs initiate recruitment through the existing, trusted relationships with the patients and communities they serve and leverage prior knowledge of patient and community preferences, needs, and interests. Both surveys revealed general preferences that baseline examinations be performed in a local HPO facility. The flexibility that will be required for successful long-term commitment and involvement is not only that which addresses variation between patient-participants but also that which accommodates the variation foreseeable for each patient-participant's interest, motivation, and ability to engage over time.
There is a fine line between motivating and alienating participants, and a fine line between, on the one hand, the need Table 3 Examples of findings from various deliberative patient-engagement activities
Key finding
Source of finding Key finding 1: balancing priorities and motivators for the PMI Open-forum discussions held at Geisinger (January 2016) with enrolled MyCode participants When discussing features that might increase participation rates, participants prioritize several features above being included as partners in the research design and process or having opportunities to learn how research will be conducted. Features prioritized, in rank order, were periodic updates about the study's progress, access to copies of data collected and individual research results, and an ability to recruit friends and family members to participate in study activities along with them.
Key finding 2: creating cohort strategies
Open-forum discussions held at Geisinger (January 2016) with enrolled MyCode participants Participants supported cohort strategies such as "Senior Siblings" (siblings older than 65 who could participate together). Participants wanted gatherings, i.e., opportunities to socialize and "do" research with others (including friends and family); however, when annual family reunions were suggested as a possible time to do this, participants said that they do not get to see family often enough and this would not be how they would want to use the precious family time they do get to enjoy. Alternative suggestions included church and community fundraiser-style events and co-worker activities. Participants wanted to feel connected to others throughout the PMI cohort and suggested use of webinars.
Key finding 3: ideas to promote involvement and retention
Open-forum discussions held at Geisinger (January 2016) with enrolled MyCode participants Participants identified several features that would make PMI "more fun, interesting, and interactive," including a research idea incubator, accelerator, or "Shark Tank"-like program; an online or mobile research dashboard to learn the status of their own specimens and data in studies and research progress; and social components (e.g., "meet-ups").
Key finding 4: input on research design, questions, and methods
Open-forum discussions held at Geisinger (January 2016) with enrolled MyCode participants Participants want the PMI to study the health impact of environmental exposures (suggesting several research priorities, e.g., water from nearby fracking activities, effects of pesticides and herbicides in the food chain, and air quality related to automobile emissions and materials); however, when discussing the inclusion of microbiome studies, participants were divided (with participants remarking that swabbing items "is just too much," emphasizing a need for "edutainment" about microbiome studies before data collection, and expressing that willingness to contribute would vary depending on whether data could be automatically transferred from monitoring devices placed in the home/office rather than requiring manual submission). Participants preferred iOS and Android devices over Windows-based ones and expressed interest in continuing to use wearables and other devices they already own.
to avoid missing data and maximize sample size and statistical power and, on the other hand, an individual participant's autonomous decision to decline some activities while remaining an active member of the PMI cohort. Accommodating life interruptions (such as needing to take a second job, caring for a new baby, or getting arrested) that might cause an individual's involvement in research activities to plummet and leveraging a person's heightened interest in research related to a particular event (such as a friend's diagnosis with a condition prompting an increased interest in a person's contribution of data, time, energy, and money to research being conducted for that disease) are important considerations. Such occurrences are likely to vary in frequency and magnitude between demographic groups. Navigating the nuanced perspectives of patients and communities, such as those learned by GHS and HFHS in their extensive and ongoing patient-engagement experience, requires skill and finesse not easily transferred between entities or newcomers. For example, there is a strong desire for a social and emotional bond (and actual interactions and communication) between members of the PMI cohort. However, this desired communitas should not be confused with intimacy. Although the ability of family members to participate is seen as a benefit, and the potential to learn about one's genetic ancestry might motivate individuals to join the PMI cohort, approaching extended families at annual reunions to participate in research activities could be received as an unwelcome intrusion. Additionally, not everyone who is interested in participating has the ability to participate in all PMI activities. This suggests a recruitment barrier and an engagement challenge-although individuals might be enrolled in the PMI and willing to contribute data from diverse sources, they might lack the necessary resources (such as a reliable Internet connection or cell signal at home needed to sync devices or submit online surveys) to contribute fully. Potential participants might want to know the full extent of activities expected of them before agreeing to join the PMI cohort. Accordingly, it would be advantageous to determine whether patient-partners have an option, at the outset, to participate at different levels of intensity.
Initial PMI plans suggest that it will include deliberative involvement of patients as partners in research (helping to develop research priorities, select methods, conduct the research, and distribute the results). Such types of engagement require considerable infrastructure and institutional commitment to support and manage. Public messaging of partnerships with patients and the public without corresponding actions could convert early champions into critics. Ongoing diligence is required to optimize engagement and implement participant-generated and -supported research priorities for PMI. Two such areas of ongoing attention for HFHS and GHS are (i) the onboarding processes for patients in various research roles (e.g., screening, matching, and training not only for patients but also for research personnel to enable a scientifically robust, ethically sound, productive, and meaningful collaboration to occur for all parties) and (ii) solicitation of patient input regarding which environmental factors, medical conditions, or health outcomes are prioritized for study.
Genomics and big data, cast as the leads, continue to bask in the PMI's spotlight; however, they can only be as strong as their supporting cast. Without patients' eagerness to participate in PMI activities, willingness to contribute biospecimens and data from diverse sources, long-term commitment, and contentment with the pace of progress, the performance of PMI genomics and big data will underachieve. We must continue to emphasize the essential role that patients-involved in PMI through precision engagement-play in realizing the potential greatness of precision medicine. Precision engagement requires significant resources and dedication to meet patients where they are (spatially, temporally, psychologically, socially, economically, etc.) and to implement strategies for research activities, recruitment, and retention that appeal to people with diverse needs, interests, and capacities for research participation; leverage the diverse motivations patients have for participating; foster communitas; and adequately accommodate life's interruptions and distractions that could limit involvement despite patientparticipants' intentions.
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